Thomas Magliery, PhD — Chief Executive Officer








Dr. Magliery has substantial expertise in protein design, directed evolution and biophysical characterization, as well as enzymological characterization. As an independent investigator, Dr. Magliery has invented a  high-throughput screen for protein thermal stability, used bioinformatics to design stable proteins, and continued to improve chemical biology methods for studying weak protein interactions in cells. Dr. Magliery has studied the enzymology and engineered the physical properties of paraoxonase-1 for chemical warfare countermeasures. In 2012, Dr. Magliery began an effort to engineer stable, high-affinity antibody fragments for use in cancer imaging which has demonstrated that several of these are effective in xenograft mice.
  As a postdoctoral fellow with Lynne Regan, Dr. Magliery developed a cell-based screen for application of combinatorial methods to protein design, applied statistical analysis to the design of protein motifs, and made substantial improvements to a GFP-based method for trapping protein interactions in living cells. As a graduate student with Peter Schultz, Dr. Magliery engineered orthogonal enzyme-tRNA pairs by directed evolution, and engineered expanded-codon tRNAs, leading to the first living organisms capable of site-specific insertion of unnatural amino acids. In 8 years at OSU, Dr. Magliery has graduated 7 Ph.D. students, 2 M.S. students, and 10 senior honors students. His lab currently hosts 9 graduate students and 3 postdocs, as well as 6 undergraduate researchers and 2 research assistants/technicians.

Edward W. Martin III, MBA — Chief Operations Officer/Co-Founder








Mr. Martin has over 20 years experience in nuclear medicine research (Neoprobe Corp. Dublin OH, and BioCrystal Ltd, Westerville Ohio.), biotechnology business management (Interthyr Corporation, Athens, OH) and operations management and logistics consulting (W.R. Grace Cambridge MA, and Bose Corporation Framingham, MA). Mr. Martin holds a Masters degree in Business Administration from Northeastern University (Boston, MA) and a Bachelors of Arts degree in Mass Communications and Marketing from Samford University (Birmingham AL).

George H. Hinkle, MS, RPh — VP Nuclear Medicine








Mr. Hinkle is an Associate Professor of Pharmacy and Radiology at The Ohio State University (OSU). He has more than 25 years experience in radiopharmaceutical research/development primarily with radiolabeled antibodies and small molecules for tumor targeting. Mr. Hinkle has experience in leading clinical trials involving radiopharmaceuticals and will coordinate the laboratory development, pre-clinical chemistry and animal imaging of radiolabeled compounds using MicroPET/CT and tissue distribution/pharmacokinetic studies. Mr. Hinkle holds a degree in Pharmacy and a masters degree in Nuclear Pharmacy, both from Purdue University (West Lafayette, IN) Mr. Hinkle provides expertise in the clinical use of radiopharmaceutical agents, as Enlyton moves radiolabeled compounds into the clinical testing stages.

 Cathy M. Mojzisik, RN, MS — VP Clinical Development

Ms. Mojzisik’s career in nursing includes over 30 years of clinical oncology research experience with over 50 peer reviewed journal articles and book chapters. As a clinical research coordinator at The Ohio State University, Ms. Mojzisik was instrumental in in the development and execution of Phase I-III clinical trials including investigations of tumor markers and radiolabeled monoclonal antibodies for intraoperative tumor detection and perioperative imaging and managed a multidisciplinary research team. She served as a member of the The James Clinical Scientific Review Committee. Her career in the pharmaceutical industry included the development of intraoperative education and training programs for Neoprobe sponsored clinical trials that were implement globally. Ms. Mojzisik has extensive experience in the contract research organization industry including monitoring clinical trials, managing clinical research associates, and serving as a senior project manager. Ms. Mojzisik holds a Bachelor of Science in Nursing degree from St. John College of Cleveland and a Master of Science in nursing degree from The Ohio State University.

Caroline Crisafulli, PMP — VP Operations







Ms. Crisafulli has over years medical device start-up experience and was the co-founder and VP-Operations for Minimally Invasive Devices, Inc. (Columbus, OH). Ms Crisafulli has over 20 years management experience in an Oncology Medical Practice. Ms Crisafulli holds a Bachelor of Science degree in Molecular Genetics from University of Illinois at Urbana-Champaign and is a Certified Project Management Professional.

Art Morelli — Business Development and Licensing









Mr. Morelli is a pharmaceutical industry professional with 30 + years of leadership experience at companies such as DuPont Merck Pharma, Elan Biopharmaceuticals, Cardinal Health, Solstice Neurosciences, Inc. and Covidien/Mallinckrodt Pharmaceuticals. At Du Pont Merck Mr. Morelli led the growth and expansion of the companies Emerging Markets pharmaceutical business in over 50 countries throughout Europe, Asia Pacific, Latin America and the Middle East regions. At Elan Biopharmaceuticals Mr. Morelli was VP of New Product Planning leading WW operations planning for the novel treatment for MS, Tysabri( natalizumab). Mr. Morelli was the co-founder and EVP of Commercial Operations for Solstice Neurosciences, Inc., a venture backed start-up which acquired the worldwide rights for Myobloc (botulinum toxin type B) from Elan. In this role, Mr. Morelli created and led the commercial infrastructure for the 150 person biopharmaceutical company located in South San Francisco, and led the expansion of the Myobloc brand into 28 countries. Recently, Art was the Vice President of Medical Affairs Operations at Covidien/Malinkrodt in St. Louis where he, reporting to the CMO, provided operations leadership to a 40 person Medical Affairs Dept. while overseeing a budget of nearly $ 30 million. In this position, Mr. Morelli successfully led the creation, planning, and launch of numerous key initiatives such as publications, investigator initiated clinical studies, REMS, and an innovative voluntary opioid safe use program, the CARES Alliance ( Art’s latest venture, Arthur F. Morelli and Associates, provides pharma companies with strategic and tactical solutions designed to optimize the effectiveness and efficiency of all aspects of their risk mitigation programs, and how to integrate risk mitigation with commercial activity. Art, the recipient of numerous sales, marketing and overall performance awards, hold a bachelor’s degree in Biology from Wabash College where he was the captain of the cross-country team, and has completed a resident advanced educational program at Harvard Business School focused on global business. Art coaches an adult competitive running team comprised of athletes from across the country.